Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Reduction of adriamycin cardiotoxicity by enoximone.

Bossa R, Bissoli M, Chiericozzi M, Cozzi R, Galatulas I, Salvatore G.

Anticancer Res. 1996 Jan-Feb;16(1):141-3.

PMID:
8615599
2.

Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group.

Chang A, Hunt M, Parkinson DR, Hochster H, Smith TJ.

Am J Clin Oncol. 1993 Apr;16(2):152-5.

PMID:
8452109
3.

Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo.

Genne P, Dimanche-Boitrel MT, Mauvernay RY, Gutierrez G, Duchamp O, Petit JM, Martin F, Chauffert B.

Cancer Res. 1992 May 15;52(10):2797-801.

4.

A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.

Alberts DS, Mason-Liddil N, Stock-Novack D, O'Toole RV, Abbott TM, Salmon SE.

Am J Clin Oncol. 1992 Apr;15(2):146-9.

PMID:
1553903
5.

Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.

Danesi R, Bernardini N, Agen C, Costa M, Zaccaro L, Pieracci D, Malvaldi G, Del Tacca M.

Cancer Chemother Pharmacol. 1992;29(4):261-5.

PMID:
1472260
6.

Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.

Miller TP, Dahlberg S, Salmon SE, Williamson SK, Belt RJ, Dana BW, Fisher RI.

J Clin Oncol. 1991 Jul;9(7):1204-9.

PMID:
2045860
7.

Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.

Green JB 3rd, Green S, O'Toole RV, Alberts DS, Nahhas WA, Wallace DL.

Invest New Drugs. 1991 May;9(2):191-3.

PMID:
1874602
8.

Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.

Rigas JR, Kris MG, Gralla RJ, Heelan RT, Marks LD.

Invest New Drugs. 1991 May;9(2):187-90.

PMID:
1651908
9.

Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach.

Somlo G, Doroshow J, Akman S, Leong L, Margolin K, McNamara M, Multhauf P, Blayney D, Morgan R, Raschko J.

Invest New Drugs. 1991 Feb;9(1):83-5.

PMID:
2026486
10.
11.

Reduction of adriamycin cardiotoxicity by a new cardiotonic agent.

Andreani A, Bossa R, Galatulas I, Ninci MA, Rambaldi M.

Anticancer Res. 1991 Jan-Feb;11(1):375-7.

PMID:
2018373
12.

Cardiotoxicity of anthracyclines.

Bossa R, Efstathiu G, Galatulas I, Nilnci MA.

In Vivo. 1991 Jan-Feb;5(1):61-3.

PMID:
1932627
13.

New anthracycline antitumor antibiotics.

Muggia FM, Green MD.

Crit Rev Oncol Hematol. 1991;11(1):43-64. Review.

PMID:
1831987
14.

A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study.

Falkson G, Cnaan A, Simson IW, Dayal Y, Falkson H, Smith TJ, Haller DG.

Am J Clin Oncol. 1990 Dec;13(6):510-5.

PMID:
2173394
15.

Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.

Martino S, Samal BA, Redman B, Flaherty L, Kraut M, Simon M, Valdivieso M.

Breast Cancer Res Treat. 1990 Dec;17(2):139-43.

PMID:
2096991
16.

Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.

Green MD, Speyer JL, Wernz JC, Colombo N, Beller U, Muggia FM, Beckman EM.

Invest New Drugs. 1990 Aug;8(3):333-6.

PMID:
2272774
17.
18.

Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.

Muss HB, Van Echo D, Korzun AH, Henderson IC, Campbell T, Vogelzang NJ, Rice MA, Wood W.

Am J Clin Oncol. 1990 Jun;13(3):233-7.

PMID:
2346128
19.

Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.

Ringenberg QS, Propert KJ, Muss HB, Weiss RB, Schilsky RL, Modeas C, Perry MC, Norton L, Green M.

Invest New Drugs. 1990 May;8(2):221-6.

PMID:
2166722
20.

Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.

Willmott N, Cummings J, Marley E, Smyth JF.

Biochem Pharmacol. 1990 Mar 15;39(6):1055-62. Erratum in: Biochem Pharmacol 1990 Jun 15;39(12):2077.

PMID:
2322293

Supplemental Content

Loading ...
Support Center